Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2053116rdf:typepubmed:Citationlld:pubmed
pubmed-article:2053116lifeskim:mentionsumls-concept:C0031327lld:lifeskim
pubmed-article:2053116lifeskim:mentionsumls-concept:C0006949lld:lifeskim
pubmed-article:2053116lifeskim:mentionsumls-concept:C0031412lld:lifeskim
pubmed-article:2053116lifeskim:mentionsumls-concept:C0205177lld:lifeskim
pubmed-article:2053116lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:2053116lifeskim:mentionsumls-concept:C0870883lld:lifeskim
pubmed-article:2053116lifeskim:mentionsumls-concept:C0054640lld:lifeskim
pubmed-article:2053116pubmed:issue2lld:pubmed
pubmed-article:2053116pubmed:dateCreated1991-7-25lld:pubmed
pubmed-article:2053116pubmed:abstractTextThe single oral dose kinetics of carbamazepine-10,11-epoxide (CBZ-E), the active metabolite of carbamazepine, were studied in six epileptic patients, stabilized on phenobarbital (PB) monotherapy, and in six drug-free health volunteers. The epoxide metabolite was administered as an enteric-coated tablet at the dose of 200 mg to the patients and at the dose of 100 mg to the volunteers. Patients had a significantly higher plasma clearance of CBZ-E than the control group (mean values +/- SD = 220.2 +/- 63.5 versus 112.5 +/- 46.0 ml/h/kg, p less than 0.007) and a significantly shorter plasma half-life (mean values +/- SD = 4.3 +/- 1.0 versus 6.7 +/- 0.8 h, p less than 0.0015). These results suggest that PB induces CBZ-E metabolism.lld:pubmed
pubmed-article:2053116pubmed:languageenglld:pubmed
pubmed-article:2053116pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2053116pubmed:citationSubsetIMlld:pubmed
pubmed-article:2053116pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2053116pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2053116pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2053116pubmed:statusMEDLINElld:pubmed
pubmed-article:2053116pubmed:monthMarlld:pubmed
pubmed-article:2053116pubmed:issn0163-4356lld:pubmed
pubmed-article:2053116pubmed:authorpubmed-author:MartinekKKlld:pubmed
pubmed-article:2053116pubmed:authorpubmed-author:PisanoLLlld:pubmed
pubmed-article:2053116pubmed:authorpubmed-author:TomsonTTlld:pubmed
pubmed-article:2053116pubmed:authorpubmed-author:FazioAAlld:pubmed
pubmed-article:2053116pubmed:authorpubmed-author:SpinaEElld:pubmed
pubmed-article:2053116pubmed:authorpubmed-author:TrioRRlld:pubmed
pubmed-article:2053116pubmed:issnTypePrintlld:pubmed
pubmed-article:2053116pubmed:volume13lld:pubmed
pubmed-article:2053116pubmed:ownerNLMlld:pubmed
pubmed-article:2053116pubmed:authorsCompleteYlld:pubmed
pubmed-article:2053116pubmed:pagination109-12lld:pubmed
pubmed-article:2053116pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:2053116pubmed:meshHeadingpubmed-meshheading:2053116-...lld:pubmed
pubmed-article:2053116pubmed:meshHeadingpubmed-meshheading:2053116-...lld:pubmed
pubmed-article:2053116pubmed:meshHeadingpubmed-meshheading:2053116-...lld:pubmed
pubmed-article:2053116pubmed:meshHeadingpubmed-meshheading:2053116-...lld:pubmed
pubmed-article:2053116pubmed:meshHeadingpubmed-meshheading:2053116-...lld:pubmed
pubmed-article:2053116pubmed:meshHeadingpubmed-meshheading:2053116-...lld:pubmed
pubmed-article:2053116pubmed:meshHeadingpubmed-meshheading:2053116-...lld:pubmed
pubmed-article:2053116pubmed:meshHeadingpubmed-meshheading:2053116-...lld:pubmed
pubmed-article:2053116pubmed:meshHeadingpubmed-meshheading:2053116-...lld:pubmed
pubmed-article:2053116pubmed:year1991lld:pubmed
pubmed-article:2053116pubmed:articleTitleEffect of phenobarbital on the pharmacokinetics of carbamazepine-10,11-epoxide, an active metabolite of carbamazepine.lld:pubmed
pubmed-article:2053116pubmed:affiliationPsychiatric Hospital, Institute of Pharmacology, Messina, Italy.lld:pubmed
pubmed-article:2053116pubmed:publicationTypeJournal Articlelld:pubmed